Journals / Çocuk Enfeksiyon Dergisi / 2010 / Cilt: 4 - Sayı: 3

Pseudomonas aeruginosa endokarditine karşı savaşı kazanmak: Vaka sunumu

Winning the battle against pseudomonas aeruginosa endocarditis: A case report

Pages
114–116
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We wish to emphasize the importance of surgical intervention and also recall the significance of lenghtening the antipseudomonal combination therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infective endocarditis is a major risk for patients with congenital heart disease and has high mortality and morbidity rates, even though there have been many advances in antimicrobial therapy and surgical intervention techniques.
📊
Key Findings & Data:Incidence of pseudomonas endocarditis has increased due to a higher frequency of drug abuse, heart surgery and bacteremia.
💡
Conclusion & Impact:We wish to emphasize the importance of surgical intervention and also recall the significance of lenghtening the antipseudomonal combination therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Infective endocarditis is a major risk for patients with congenital heart disease and has high mortality and morbidity rates, even though there have been many advances in antimicrobial therapy and surgical intervention techniques. Gram positive microorganisms, such as staphylococcus and streptococcus species, are the most commonly isolated organisms. Pseudomonas aeruginosa is a rare causative organism for infective endocarditis. It usually affects the right side of the heart, which is usually seen in intravenous drug users. Incidence of pseudomonas endocarditis has increased due to a higher frequency of drug abuse, heart surgery and bacteremia. Mortality from pseudomonas infective endocarditis remains high despite optimal use of available antibacterial agents and also the treatment plan is very challenging as there is no consensus to date. We report a patient with tetralogy of Fallot and recurrent P. aeruginosa endocarditis after corrective cardiac surgery. We wish to emphasize the importance of surgical intervention and also recall the significance of lenghtening the antipseudomonal combination therapy.

Özet

Enfektif endokardit, konjenital kalp hastalığı bulunan hastalarda, antimikrobiyal ve cerrahi alanında olan gelişmelere rağmen önemli bir morbidite ve mortalite nedenidir. Stafilokok ve streptokok gibi gram pozitif mikroorganizmalar en sık izole edilen etkenlerdendir. Pseudomonas aeruginosa enfektif endokarditin nadir görülen patojenlerindendir. Genellikle ilaç bağımlılarında görülmektedir ve kalbin sağ tarafını etkilemektedir. Artan ilaç bağımlılığı, kalp cerrahisi ve bakteriyemi nedeniyle pseudomonas endokarditinin sıklığı da artış göstermiştir. Pseudomonasa bağlı enfektif endokarditin yol açtığı mortalite, uygun antimikrobiyel ajanların kullanımına rağmen halen yüksek seyretmektedir ve tedavi planı üzerinde henüz tam olarak uzlaşılamadığından zorlayıcı olmaya devam etmektedir. Bu vaka sunumunda Fallot tetralojisi olan bir hastanın cerrahi sonrası tekrarlayan P. aeruginosa endokarditi sunularak cerrahinin ve antipsödomonal kombinasyon tedavinin uzatılmasının önemi vurgulanmıştır.

🔖

Cite This Article

PARLAKAY, A. Ö., KARA, A., ÇELİK, İ., CENGİZ, A. B., KARAGÖZ, T., DEVRİM, İ., CEYHAN, M. (2010). Pseudomonas aeruginosa endokarditine karşı savaşı kazanmak: Vaka sunumu. Çocuk Enfeksiyon Dergisi, Cilt: 4 - Sayı: 3, 114–116. https://ajindex.com/articles/218169

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Saiman L, Prince A, Gersony WM. Pediatric infective endocarditis in the modern era. J Pediatr 1993; 122: 847-53
  2. Saraiva RM, Camillis LF, Francisco RM, Gomes MV. Isolated pulmonary valve Pseudomonas aeruginosa endocarditis related to catheter embolism. Int J Cardiol 2002; 83: 83-4. PMid:11959388 3. Cohen PS, Maguire JH, Weinstein L. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. Prog Cardiovasc Dis 1980; 22: 205-42
  3. Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis 1990; 12: 693-702. PMid:2385771 5. Morrison AJ Jr, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis 1984; 6: 627-42
  4. Bicanic TA, Eykyn SJ. Hospital-acquired, native valve endocarditis caused by Pseudomonas aeruginosa. J Infect 2002; 44: 137-9. PMid:12076074 7. Costerton JW. The etiology and persistence of cryptic bacterial infections: a hypothesis. Rev Infect Dis 1984; 6: 608-16
  5. Bayer AS, Crowell DJ, Yih J, Bradley DW, Norman DC. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis. J Infect Dis 1988; 158: 355-9. PMid:3042875 9. Llosa JC, Gosalbez F, Cofino JL, Naya JL, Valle JM. Pulmonary valve endocarditis: mid-term follow up of pulmonary valvectomies. J Heart Valve Dis 2000; 9: 359-63. PMid:10888091 10. Iaconis JP, Pitkin DH, Sheikh W, Nadler HL. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997; 24: 191-6.